Dipeptidyl peptidase IV inhibitors as novel regulators of vascular disease

Journal article

Dipeptidyl peptidase IV (DPP-IV) has been revealed as an adipokine with potential relevance in cardiovascular disease (CVD), while clinically used DPP-IV inhibitors have demonstrated beneficial cardiovascular effects in several experimental studies. Perivascular adipose tissue (PVAT) is a unique adipose tissue depot in close anatomical proximity and bidirectional functional interaction with the vascular wall, which is a source of DPP-IV and its biology may be influenced by DPP-IV inhibition. Recently, DPP-IV inhibition has been associated with decreased local inflammation and oxidative stress both in the vascular wall and the PVAT, potentially regulating atherogenesis progression in vivo. DPP-IV inhibition may thus be a promising target in cardiovascular disease. However, the exact pleiotropic mechanisms that underlie the cardiovascular effects of DPP-IV inhibition need to be clarified, while the in vivo benefit of DPP-IV inhibition in humans remains unclear.

Authors: Akoumianakis, I; Antoniades, C

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: Elsevier
• Journal: Vascular Pharmacology
• Volume: 96-98
• Pages: 1-4
• Publication date: 2017-07-08
• Acceptance date: 2017-07-01
• DOI: 10.1016/j.vph.2017.07.001
• EISSN: 1879-3649
• ISSN: 1537-1891
• Language: English
• Keywords: oxidative stress; DPP-IV inhibitors; perivascular adipose tissue; atherosclerosis